| Year |
Citation |
Score |
| 2020 |
Singhal M, Gengenbacher N, La Porta S, Gehrs S, Shi J, Kamiyama M, Bodenmiller DM, Fischl A, Schieb B, Besemfelder E, Chintharlapalli S, Augustin HG. Preclinical validation of a novel metastasis-inhibiting Tie1 function-blocking antibody. Embo Molecular Medicine. e11164. PMID 32302470 DOI: 10.15252/Emmm.201911164 |
0.374 |
|
| 2020 |
Li Z, Korhonen EA, Merlini A, Strauss J, Wihuri E, Nurmi H, Antila S, Paech J, Deutsch U, Engelhardt B, Chintharlapalli S, Koh GY, Flügel A, Alitalo K. Angiopoietin-2 blockade ameliorates autoimmune neuroinflammation by inhibiting leukocyte recruitment into the CNS. The Journal of Clinical Investigation. PMID 32149735 DOI: 10.1172/Jci130308 |
0.345 |
|
| 2020 |
Chintharlapalli S, Fischl A, Yu CP, Iversen P. Abstract 1675: Enhanced antitumor effect of dual EGFR and VEGFR2 inhibition in EGFR-mutated non-small cell lung cancer (NSCLC) patient-derived tumor xenograft (PDX) models Cancer Research. 80: 1675-1675. DOI: 10.1158/1538-7445.Am2020-1675 |
0.353 |
|
| 2019 |
Fischl AS, Wang X, Falcon BL, Almonte-Baldonado R, Bodenmiller D, Evans G, Stewart J, Wilson T, Hipskind P, Manro JR, Uhlik MT, Chintharlapalli S, Gerald D, Alsop DC, Benjamin LE, et al. Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition. Molecular Cancer Therapeutics. PMID 30787172 DOI: 10.1158/1535-7163.Mct-18-0548 |
0.451 |
|
| 2018 |
Emmerson PJ, Duffin KL, Chintharlapalli S, Wu X. GDF15 and Growth Control. Frontiers in Physiology. 9: 1712. PMID 30542297 DOI: 10.3389/Fphys.2018.01712 |
0.33 |
|
| 2018 |
Swearingen M, Falcon B, Chintharlapalli S, Uhlik M. An Endothelial Cell/Mesenchymal Stem Cell Coculture Cord Formation Assay to Model Vascular Biology In Vitro. Methods of Molecular Biology. 1683: 371-382. PMID 29082503 DOI: 10.1007/978-1-4939-7357-6_21 |
0.357 |
|
| 2017 |
Lee L, Huber L, Stewart J, Mathews M, Falcon B, Chintharlapalli S. Evaluation of AFP expression as a predictive marker for response to anti-VEGFR-2 inhibition. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: iii19-iii20. PMID 32135817 DOI: 10.1093/Annonc/Mdx261.024 |
0.302 |
|
| 2017 |
Um SL, Peek VL, Stephens JR, Baker JA, Cannon HK, Cook JD, Wulur IH, Agyei R, Chintharlapalli S, Evans RJ, Feaver WJ, Huber L, Lee LN, Liu L, Ma L, et al. Abstract 519: Antitumor activity of MET antibody emibetuzumab (LY2875358) in combination with EGFR inhibitors in erlotinib resistant (ER) xenograft mouse models Cancer Research. 77: 519-519. DOI: 10.1158/1538-7445.Am2017-519 |
0.379 |
|
| 2017 |
Tetreault J, Chintharlapalli S, Leung D, Gerald D, Lee L, Almonte-Baldonado R, Huber L, Xu J, Ramamurthy B, Pereira J, Croy J, Lu J, Liu L. Abstract 3090: LY3207447, a tetravalent bispecific antibody targeting VEGFR2 and angiopoietin-2, provides a more efficient anti-angiogenic therapy and an alternative for combination Cancer Research. 77: 3090-3090. DOI: 10.1158/1538-7445.Am2017-3090 |
0.409 |
|
| 2017 |
Bodenmiller DM, Stewart JA, Evans GF, Peek VL, Stephens JR, Lin X, Iyer S, Falcon BL, Chintharlapalli S, Yan SB, Fischl AS. Abstract 1823: Characterization of the anti-angiogenic properties of merestinib (LY2801653), an oncokinase inhibitor Cancer Research. 77: 1823-1823. DOI: 10.1158/1538-7445.Am2017-1823 |
0.425 |
|
| 2016 |
Falcon BL, Chintharlapalli S, Uhlik MT, Pytowski B. Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents Pharmacology & Therapeutics. 164: 204-225. PMID 27288725 DOI: 10.1016/J.Pharmthera.2016.06.001 |
0.414 |
|
| 2016 |
Uhlik MT, Liu J, Falcon BL, Iyer S, Stewart J, Celikkaya H, O'Mahony M, Sevinsky C, Lowes C, Douglass L, Jeffries C, Bodenmiller D, Chintharlapalli S, Fischl A, Gerald D, et al. Stromal-Based Signatures for the Classification of Gastric Cancer. Cancer Research. 76: 2573-2586. PMID 27197264 DOI: 10.1158/0008-5472.Can-16-0022 |
0.394 |
|
| 2016 |
Wu W, Stewart J, King C, Jones B, Flack R, Pratt S, Berryman R, Swearingen M, Bodenmiller D, Lin X, Uhlik M, Falcon B, Fischl A, Manro J, Tiu R, ... Chintharlapalli S, et al. Abstract 930: Combined inhibition of pan-RAF and VEGFR-2 mediates antitumor activity in KRAS mutant non-small cell lung cancer (NSCLC) through enhanced inhibition of tumor angiogenesis and growth Cancer Research. 76: 930-930. DOI: 10.1158/1538-7445.Am2016-930 |
0.501 |
|
| 2016 |
Chintharlapalli SR, Croy JE, Leung D, Gerald D, Lu J, Iversen PW, Lee LN, Huber L, Tetreault J, Almonte-Baldonado R, Xu J, Ramamurthy B, Pereira JA, Chow C, Hanauske A, et al. Abstract 3259: LY3127804, a novel anti-Angiopoietin-2 antibody in combination with an anti-VEGFR2 antibody potently inhibits angiogenesis, tumor growth and metastasis Cancer Research. 76: 3259-3259. DOI: 10.1158/1538-7445.Am2016-3259 |
0.39 |
|
| 2015 |
Shen Y, Zeng L, Novosyadlyy R, Forest A, Zhu A, Korytko A, Zhang H, Eastman SW, Topper M, Hindi S, Covino N, Persaud K, Kang Y, Burtrum D, Surguladze D, ... ... Chintharlapalli S, et al. A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation. Mabs. 0. PMID 26073904 DOI: 10.1080/19420862.2015.1055442 |
0.411 |
|
| 2014 |
Falcon BL, Swearingen M, Gough WH, Lee L, Foreman R, Uhlik M, Hanson JC, Lee JA, McClure DB, Chintharlapalli S. An in vitro cord formation assay identifies unique vascular phenotypes associated with angiogenic growth factors. Plos One. 9: e106901. PMID 25210890 DOI: 10.1371/Journal.Pone.0106901 |
0.374 |
|
| 2014 |
Liu J, Falcon BL, Nagy JA, Jaminet SS, Li D, Doman TN, Chintharlapalli S, Pytowski B, Uhlik MT, Dvorak H, Benjamin L, Fischl AS. Abstract 2359: Bioinformatics analysis of an Ad-VEGF flank angiogenesis model identifies vessel subtype gene signatures: Implications for anti-VEGF therapy Cancer Research. 74: 2359-2359. DOI: 10.1158/1538-7445.Am2014-2359 |
0.38 |
|
| 2013 |
Falcon BL, O'Clair B, McClure D, Evans GF, Stewart J, Swearingen ML, Chen Y, Allard K, Lee LN, Neote K, McEwen DP, Uhlik MT, Chintharlapalli S. Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition. Journal of Hematology & Oncology. 6: 31. PMID 23622716 DOI: 10.1186/1756-8722-6-31 |
0.353 |
|
| 2013 |
Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Research. 73: 1649-57. PMID 23467610 DOI: 10.1158/0008-5472.Can-12-4697 |
0.333 |
|
| 2012 |
Kim K, Chadalapaka G, Pathi SS, Jin UH, Lee JS, Park YY, Cho SG, Chintharlapalli S, Safe S. Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b-25 clusters. Molecular Cancer Therapeutics. 11: 1852-62. PMID 22752225 DOI: 10.1158/1535-7163.Mct-12-0181 |
0.793 |
|
| 2011 |
Meier T, Uhlik M, Chintharlapalli S, Dowless M, Van Horn R, Stewart J, Blosser W, Cook J, Young D, Ye X, Evans G, Credille K, Ballard D, Huber L, Capen A, et al. Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization. Molecular Cancer Therapeutics. 10: 2168-78. PMID 21903607 DOI: 10.1158/1535-7163.Mct-11-0323 |
0.548 |
|
| 2011 |
Chintharlapalli S, Papineni S, Lei P, Pathi S, Safe S. Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors. Bmc Cancer. 11: 371. PMID 21864401 DOI: 10.1186/1471-2407-11-371 |
0.828 |
|
| 2011 |
Chintharlapalli S, Papineni S, Lee SO, Lei P, Jin UH, Sherman SI, Santarpia L, Safe S. Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins. Molecular Carcinogenesis. 50: 655-67. PMID 21268135 DOI: 10.1002/Mc.20738 |
0.801 |
|
| 2010 |
Kim JH, Jung JY, Shim JH, Kim J, Choi KH, Shin JA, Choi ES, Lee SO, Chintharlapalli S, Kwon KH, Leem DH, Cho NP, Cho SD. Apoptotic Effect of Tolfenamic Acid in KB Human Oral Cancer Cells: Possible Involvement of the p38 MAPK Pathway. Journal of Clinical Biochemistry and Nutrition. 47: 74-80. PMID 20664734 DOI: 10.3164/Jcbn.10-02 |
0.599 |
|
| 2010 |
Lee SO, Abdelrahim M, Yoon K, Chintharlapalli S, Papineni S, Kim K, Wang H, Safe S. Inactivation of the orphan nuclear receptor TR3/Nur77 inhibits pancreatic cancer cell and tumor growth. Cancer Research. 70: 6824-36. PMID 20660371 DOI: 10.1158/0008-5472.Can-10-1992 |
0.839 |
|
| 2010 |
Cho SD, Lee SO, Chintharlapalli S, Abdelrahim M, Khan S, Yoon K, Kamat AM, Safe S. Activation of nerve growth factor-induced B alpha by methylene-substituted diindolylmethanes in bladder cancer cells induces apoptosis and inhibits tumor growth. Molecular Pharmacology. 77: 396-404. PMID 20023005 DOI: 10.1124/Mol.109.061143 |
0.782 |
|
| 2010 |
Choi KH, Kim HK, Kim JH, Choi ES, Shin JA, Lee SO, Chintharlapalli S, Safe S, Abdelrahim M, Kong G, Choi HS, Jung JY, Cho HT, Cho NP, Cho SD. The p38 MAPK pathway is critical for 5,5'-dibromodiindolylmethane-induced apoptosis to prevent oral squamous carcinoma cells. European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (Ecp). 19: 153-9. PMID 19949342 DOI: 10.1097/Cej.0B013E328333D088 |
0.643 |
|
| 2010 |
Guo J, Chintharlapalli S, Lee SO, Cho SD, Lei P, Papineni S, Safe S. Peroxisome proliferator-activated receptor gamma-dependent activity of indole ring-substituted 1,1-bis(3'-indolyl)-1-(p-biphenyl)methanes in cancer cells. Cancer Chemotherapy and Pharmacology. 66: 141-50. PMID 19823826 DOI: 10.1007/S00280-009-1144-0 |
0.78 |
|
| 2010 |
Zeng W, Wortinger M, Yang WJ, Peek V, Yan L, Lu J, Chow C, Vaillancourt P, Davies J, Denning I, Weir S, McClure D, Chintharlapalli S, Liu L. Abstract 2583: LA480, a bivalent humanized c-Met monoclonal antibody, inhibits tumor growth without eliciting significant agonist activity Cancer Research. 70: 2583-2583. DOI: 10.1158/1538-7445.Am10-2583 |
0.514 |
|
| 2009 |
Lee SO, Chintharlapalli S, Liu S, Papineni S, Cho SD, Yoon K, Safe S. p21 expression is induced by activation of nuclear nerve growth factor-induced Balpha (Nur77) in pancreatic cancer cells. Molecular Cancer Research : McR. 7: 1169-78. PMID 19584258 DOI: 10.1158/1541-7786.Mcr-08-0473 |
0.819 |
|
| 2009 |
Chintharlapalli S, Papineni S, Abdelrahim M, Abudayyeh A, Jutooru I, Chadalapaka G, Wu F, Mertens-Talcott S, Vanderlaag K, Cho SD, Smith R, Safe S. Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon cancer cells. International Journal of Cancer. 125: 1965-74. PMID 19582879 DOI: 10.1002/Ijc.24530 |
0.801 |
|
| 2009 |
Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, Baker C, Herrera L, Safe S. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis. 30: 1193-201. PMID 19406933 DOI: 10.1093/Carcin/Bgp092 |
0.825 |
|
| 2009 |
Jutooru I, Chadalapaka G, Chintharlapalli S, Papineni S, Safe S. Induction of apoptosis and nonsteroidal anti-inflammatory drug-activated gene 1 in pancreatic cancer cells by a glycyrrhetinic acid derivative. Molecular Carcinogenesis. 48: 692-702. PMID 19125423 DOI: 10.1002/Mc.20518 |
0.834 |
|
| 2008 |
Inamoto T, Papineni S, Chintharlapalli S, Cho SD, Safe S, Kamat AM. 1,1-Bis(3'-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. Molecular Cancer Therapeutics. 7: 3825-33. PMID 19074857 DOI: 10.1158/1535-7163.Mct-08-0730 |
0.819 |
|
| 2008 |
Cho SD, Chintharlapalli S, Abdelrahim M, Papineni S, Liu S, Guo J, Lei P, Abudayyeh A, Safe S. 5,5'-Dibromo-bis(3'-indolyl)methane induces Kruppel-like factor 4 and p21 in colon cancer cells. Molecular Cancer Therapeutics. 7: 2109-20. PMID 18645021 DOI: 10.1158/1535-7163.Mct-07-2311 |
0.804 |
|
| 2008 |
Chadalapaka G, Jutooru I, Chintharlapalli S, Papineni S, Smith R, Li X, Safe S. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Research. 68: 5345-54. PMID 18593936 DOI: 10.1158/0008-5472.Can-07-6805 |
0.827 |
|
| 2008 |
Safe S, Papineni S, Chintharlapalli S. Cancer chemotherapy with indole-3-carbinol, bis(3'-indolyl)methane and synthetic analogs. Cancer Letters. 269: 326-38. PMID 18501502 DOI: 10.1016/J.Canlet.2008.04.021 |
0.821 |
|
| 2008 |
Lei P, Abdelrahim M, Cho SD, Liu S, Chintharlapalli S, Safe S. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through activation of c-jun N-terminal kinase. Carcinogenesis. 29: 1139-47. PMID 18460448 DOI: 10.1093/Carcin/Bgn103 |
0.668 |
|
| 2008 |
Hong J, Samudio I, Chintharlapalli S, Safe S. 1,1-bis(3'-indolyl)-1-(p-substituted phenyl)methanes decrease mitochondrial membrane potential and induce apoptosis in endometrial and other cancer cell lines. Molecular Carcinogenesis. 47: 492-507. PMID 18085536 DOI: 10.1002/Mc.20407 |
0.709 |
|
| 2008 |
York M, Abdelrahim M, Chintharlapalli S, Lucero SD, Safe S. 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes induce apoptosis and inhibit renal cell carcinoma growth. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6743-52. PMID 18006776 DOI: 10.1158/1078-0432.Ccr-07-0967 |
0.626 |
|
| 2008 |
Papineni S, Chintharlapalli S, Safe S. Methyl 2-cyano-3,11-dioxo-18 beta-olean-1,12-dien-30-oate is a peroxisome proliferator-activated receptor-gamma agonist that induces receptor-independent apoptosis in LNCaP prostate cancer cells. Molecular Pharmacology. 73: 553-65. PMID 17989348 DOI: 10.1124/Mol.107.041285 |
0.777 |
|
| 2008 |
Cho SD, Lei P, Abdelrahim M, Yoon K, Liu S, Guo J, Papineni S, Chintharlapalli S, Safe S. 1,1-bis(3'-indolyl)-1-(p-methoxyphenyl)methane activates Nur77-independent proapoptotic responses in colon cancer cells. Molecular Carcinogenesis. 47: 252-63. PMID 17957723 DOI: 10.1002/Mc.20378 |
0.808 |
|
| 2008 |
Inamoto T, Papineni S, Chintharlapalli S, Cho S, Black PC, McConkey DJ, Dinney CP, Safe SH, Kamat AM. A NOVEL ACTIVATOR OF THE ORPHAN NUCLEAR RECEPTOR Nurr1 INHIBITS BLADDER TUMOR GROWTH Journal of Urology. 179: 369-369. DOI: 10.1016/S0022-5347(08)61081-2 |
0.751 |
|
| 2007 |
Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Research. 67: 11001-11. PMID 18006846 DOI: 10.1158/0008-5472.Can-07-2416 |
0.574 |
|
| 2007 |
Chintharlapalli S, Papineni S, Liu S, Jutooru I, Chadalapaka G, Cho SD, Murthy RS, You Y, Safe S. 2-cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor gamma in colon and pancreatic cancer cells. Carcinogenesis. 28: 2337-46. PMID 17724373 DOI: 10.1093/Carcin/Bgm189 |
0.829 |
|
| 2007 |
Reddivari L, Vanamala J, Chintharlapalli S, Safe SH, Miller JC. Anthocyanin fraction from potato extracts is cytotoxic to prostate cancer cells through activation of caspase-dependent and caspase-independent pathways. Carcinogenesis. 28: 2227-35. PMID 17522067 DOI: 10.1093/Carcin/Bgm117 |
0.615 |
|
| 2007 |
Chintharlapalli S, Papineni S, Jutooru I, McAlees A, Safe S. Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor {gamma} agonists in colon cancer cells. Molecular Cancer Therapeutics. 6: 1588-98. PMID 17513608 DOI: 10.1158/1535-7163.Mct-07-0022 |
0.823 |
|
| 2007 |
Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Research. 67: 2816-23. PMID 17363604 DOI: 10.1158/0008-5472.Can-06-3735 |
0.797 |
|
| 2007 |
Cho SD, Yoon K, Chintharlapalli S, Abdelrahim M, Lei P, Hamilton S, Khan S, Ramaiah SK, Safe S. Nur77 agonists induce proapoptotic genes and responses in colon cancer cells through nuclear receptor-dependent and nuclear receptor-independent pathways. Cancer Research. 67: 674-83. PMID 17234778 DOI: 10.1158/0008-5472.Can-06-2907 |
0.779 |
|
| 2007 |
Chintharlapalli S, Papineni S, Safe S. 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes inhibit growth, induce apoptosis, and decrease the androgen receptor in LNCaP prostate cancer cells through peroxisome proliferator-activated receptor gamma-independent pathways. Molecular Pharmacology. 71: 558-69. PMID 17093136 DOI: 10.1124/Mol.106.028696 |
0.812 |
|
| 2006 |
Chintharlapalli S, Papineni S, Safe S. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPARgamma-dependent and PPARgamma-independent pathways. Molecular Cancer Therapeutics. 5: 1362-70. PMID 16731770 DOI: 10.1158/1535-7163.Mct-06-0002 |
0.828 |
|
| 2006 |
Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM. Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Research. 66: 412-8. PMID 16397256 DOI: 10.1158/0008-5472.Can-05-2755 |
0.685 |
|
| 2005 |
Chintharlapalli S, Papineni S, Baek SJ, Liu S, Safe S. 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1. Molecular Pharmacology. 68: 1782-92. PMID 16155208 DOI: 10.1124/Mol.105.017046 |
0.834 |
|
| 2005 |
Chintharlapalli S, Burghardt R, Papineni S, Ramaiah S, Yoon K, Safe S. Activation of Nur77 by selected 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes induces apoptosis through nuclear pathways. The Journal of Biological Chemistry. 280: 24903-14. PMID 15871945 DOI: 10.1074/Jbc.M500107200 |
0.823 |
|
| 2005 |
Chintharlapalli S, Papineni S, Konopleva M, Andreef M, Samudio I, Safe S. 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways. Molecular Pharmacology. 68: 119-28. PMID 15798084 DOI: 10.1124/Mol.105.011437 |
0.847 |
|
| 2005 |
Chintharlapalli SR, Jasti M, Malladi S, Parsa KV, Ballestero RP, González-García M. BMRP is a Bcl-2 binding protein that induces apoptosis. Journal of Cellular Biochemistry. 94: 611-26. PMID 15547950 DOI: 10.1002/Jcb.20292 |
0.415 |
|
| 2005 |
Kassouf W, Safe S, Abdelrahim M, Chintharlapalli S, Nelkin GM, Kamat AM. 778: Activity of Novel Agonists of Peroxisome Proliferator-Activated Receptor Gamma (Ppargamma) Against Human Transitional Cell Tumors Journal of Urology. 173: 211-211. DOI: 10.1016/S0022-5347(18)34947-4 |
0.568 |
|
| 2004 |
Chintharlapalli S, Smith R, Samudio I, Zhang W, Safe S. 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes induce peroxisome proliferator-activated receptor gamma-mediated growth inhibition, transactivation, and differentiation markers in colon cancer cells. Cancer Research. 64: 5994-6001. PMID 15342379 DOI: 10.1158/0008-5472.Can-04-0399 |
0.77 |
|
| Show low-probability matches. |